786 related articles for article (PubMed ID: 26366626)
1. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
2. Hydroxycarbamide: clinical aspects.
Ware RE
C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
4. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
5. Optimizing hydroxyurea therapy for sickle cell anemia.
Ware RE
Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
[TBL] [Abstract][Full Text] [Related]
6. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
Dong M; Mizuno T; Vinks AA
Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
DeBaun MR
Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
9. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
[TBL] [Abstract][Full Text] [Related]
11. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for sickle cell anemia.
Singh PC; Ballas SK
Expert Opin Emerg Drugs; 2015 Mar; 20(1):47-61. PubMed ID: 25431087
[TBL] [Abstract][Full Text] [Related]
13. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
15. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Brandow AM; Panepinto JA
Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
[TBL] [Abstract][Full Text] [Related]
16. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea: Analytical techniques and quantitative analysis.
Marahatta A; Ware RE
Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
[TBL] [Abstract][Full Text] [Related]
19. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
20. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
[No Abstract] [Full Text] [Related]
[Next] [New Search]